Elevated serum homocysteine levels associated with poor recurrence-free and overall survival in patients with colorectal cancer

  • 0Department of Gastrointestinal Gland Surgery, The First Affiliated Hospital, Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China.

|

|

Summary

This summary is machine-generated.

Elevated homocysteine (HCY) levels predict poor survival in colorectal cancer (CRC) patients. Higher HCY indicates increased mortality risk and can be used with other markers for better prognosis prediction.

Area Of Science

  • Oncology
  • Clinical Biochemistry

Background

  • Colorectal cancer (CRC) poses a significant global health challenge.
  • Identifying reliable prognostic markers for CRC patients is crucial for improving outcomes.

Purpose Of The Study

  • To investigate the prognostic value of serum homocysteine (HCY) levels in predicting recurrence-free survival (RFS) and overall survival (OS) in CRC.
  • To evaluate the potential of HCY as a supplementary marker alongside existing prognostic tools.

Main Methods

  • Retrospective analysis of 1272 colorectal cancer patients.
  • Statistical analysis including multivariate analysis and subgroup analysis.
  • Development and validation of HCY-based prognostic nomograms.

Main Results

  • Elevated HCY levels (cutoff 15.2 μmol/L) were significantly associated with poorer RFS and OS.
  • High HCY was linked to older age, male gender, larger tumors, elevated CEA, and increased healthcare costs.
  • Multivariate analysis indicated a 55.7% increased risk of adverse RFS and 61.4% increased risk of adverse OS with HCY > 15.2 μmol/L.
  • HCY levels demonstrated value in supplementing CEA and pathological staging.

Conclusions

  • Elevated serum HCY is a strong independent predictor of poor RFS and OS in CRC patients.
  • HCY-based prognostic models offer improved discrimination and calibration compared to traditional staging systems.
  • HCY holds potential as a valuable biomarker for comprehensive CRC prognosis assessment.